Forecast

The analysts' average price target is +23,17€ (+77,68%). The median is +24,89€ (+90,87%).

Buy	9
Hold	1
Sell	1

News Go to news feed

Dynavax president exercises 114,000 options and sells shares amid Sanofi acquisition

David Novack, President & COO of Dynavax, exercised 114,000 stock options and immediately sold the resulting shares for about $1.8 million, leaving him with 63,344 shares (≈0.05% of outstanding). The options exercised comprised 20,000 at $6.80 and 94,000 at $10.47, producing net proceeds of roughly $680,000 after costs. The transaction occurred as Dynavax shares traded near the $15.50 per-share acquisition price agreed with Sanofi. » More on finance.yahoo.com
Dynavax to be acquired by Sanofi for $2.2 billion; shares jump 38%

Dynavax agreed to be acquired by Sanofi for $2.2 billion, with an offer of $15.50 per share representing about a 39% premium to the Dec. 23 close. The deal brings Dynavax’s adult hepatitis B vaccine Heplisav-B and shingles candidate Z-1018 into Sanofi’s portfolio. Dynavax said Sanofi’s global scale will help maximize the vaccines’ commercial and development potential. » More on finance.yahoo.com
Dynavax secures exclusive license for Vaxart oral COVID-19 vaccine for $25m

Dynavax has entered a worldwide exclusive license agreement with Vaxart to develop and commercialize Vaxart’s oral COVID-19 vaccine, paying an upfront $25m plus a $5m equity stake. Vaxart remains responsible for development until completion of the ongoing Phase‑2b study; Dynavax may assume further development at the end of 2026 for an additional $50m. Milestone payments to Vaxart could total up to $620m, plus royalties on future sales; the Phase‑2b trial with about 5,400 participants is funded under Project NextGen. Dynavax is described as financially well positioned but is currently not profitable; the company also announced a new $100m share buyback program. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Dynavax Technologies Co. has already paid 0,26€ in dividends. The last payout was in March 2022.

Financials

In the last quarter, Dynavax Technologies Co. had revenue of 80.85m€ and net profit of 22.95m€

(EUR)	Sep 2025	YoY
Revenue	+80.85m	-
Gross profit	+68.57m	-
Net profit	+22.95m	-
EBITDA	+27.17m	-

Fundamentals

Metric	Value
Market capitalization	+1.56b€
Number of shares	117.42m
52-week high/low	+13,50€ - +7,89€
Dividends	No
Beta	0,93
P/E ratio	−40,79
PEG ratio	+0,08
P/B ratio	+3,40
P/S ratio	+7,04

Company profile

Dynavax Technologies Corporation, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entwicklung und Vermarktung neuartiger Impfstoffe in den Vereinigten Staaten. Das Unternehmen vermarktet HEPLISAV-B, einen Hepatitis-B-Impfstoff zur Vorbeugung von Infektionen, die durch alle bekannten Subtypen des Hepatitis-B-Virus im Alter von 18 Jahren und älter in den Vereinigten Staaten und Europa verursacht werden. Das Unternehmen produziert und vertreibt auch das Adjuvans CpG 1018, das in HEPLISAV-B verwendet wird. Dynavax Technologies Corporation hat eine Kooperationsvereinbarung mit Valneva Scotland Limited, eine Vereinbarung mit Serum Institute of India Pvt. Ltd. und eine Unterlizenzvereinbarung mit Merck, Sharp & Dohme Corp. Das Unternehmen war früher unter dem Namen Double Helix Corporation bekannt und änderte im September 1996 seinen Namen in Dynavax Technologies Corporation. Die Dynavax Technologies Corporation wurde 1996 gegründet und hat ihren Hauptsitz in Emeryville, Kalifornien.